Why Kura Oncology, Inc.’s (KURA) Stock Is Up 7.00%
As of Friday, August 21, Kura Oncology, Inc.’s KURA share price has surged by 7.00%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Commentary & Analysis
Why Kura Oncology, Inc.’s (KURA) Stock Is Up 10.47%
As of Tuesday, August 18, Kura Oncology, Inc.’s KURA share price has surged by 10.47%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Kura Oncology, Inc.’s (KURA) Stock Is Up 12.37%
As of Thursday, August 13, Kura Oncology, Inc.’s KURA share price has surged by 12.37%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About Kura Oncology, Inc.'s Q3 Earnings
Kura Oncology, Inc.'s fiscal Q3 earnings report was released on Wednesday, August 12. Let's dive in to see if (KURA) missed or beat analyst's expectations.Jenna Brashear
Is Kura Oncology, Inc. (KURA) Overvalued?
We dive into why Kura Oncology, Inc. (KURA) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | KURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,057.7 | $292.6 | 45% |
|
| Shares Out (Mil) | 88.9 | 54.4 | 60% |
|
| Institutional Ownership | 98.0% | 93.2% | 77% |
|
| Float (Mil) | 70.5 | 40.2 | 55% |
|
| Beta | 0.38 | 0.94 | 22% |
|
| Avg Daily Volume (000s) | 2,443 | 544 | 84% |
|
| Price Change (52-week) |
68.7% | 59.7% | 85% |
|
| Growth | KURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (25.5%) | (10.1%) | 16% |
|
| EPS (5yr) | (13.5%) | 16.0% | 19 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.6%) | (15.6%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 8 | 9 | |
| Current EPS | ($0.807) | ($3.225) | ($2.300) | |
| Month Ago EPS | ($0.892) | ($3.442) | ($2.580) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 2 | 0 | 1 | |
| Three Months Ago EPS | ($0.926) | ($3.520) | ($2.553) | |
| Year/Year Chg | 4.9% | 1.5% | (40.0%) | |
| Financials | KURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $77 | $37 | 24% |
|
| Net Income (TTM) (Mil) | ($297) | ($43) | 5% |
|
| EPS (TTM) | ($3.361) | ($1.400) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($112) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($12) | $2 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $19 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $403 | $164 | 33% |
|
| Valuation | KURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 22.02 | 2.83 | 96% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | KURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (236.7%) | 64.2% | 1% |
|
| Net Margin | (384.3%) | (75.9%) | 3% |
|
| ROA | (46.7%) | (47.5%) | 12% |
|
| ROE | (167.7%) | (55.0%) | 5% |
|
| Liabilities to Assets | 91.8% | 29.6% | 89% |
|
| F-Score | 2 | 3 | 7% |
|
Kura Oncology, Inc. did not pass any screens on 8/21/2026.
